Pyxis Oncology (PYXS) Total Non-Current Liabilities (2020 - 2024)

Pyxis Oncology (PYXS) has 5 years of Total Non-Current Liabilities data on file, last reported at $41.6 million in Q3 2024.

• On a quarterly basis, Total Non-Current Liabilities fell 14.6% year-over-year to $41.6 million in Q3 2024; TTM through Sep 2024 was $41.6 million, a 14.6% decrease from a year earlier, with the FY2023 full-year figure at $48.0 million, down 5.01% from the prior year.
• Total Non-Current Liabilities for Q3 2024 stood at $41.6 million, up from $38.6 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for PYXS reached as high as $50.6 million in Q4 2022 and fell as low as -$3.4 million in Q1 2021.
• Historically, Total Non-Current Liabilities has averaged $29.6 million across 5 years, with a median of $32.9 million in 2022.
• Across the five-year window, Total Non-Current Liabilities soared 664.32% in 2022 and slipped 14.6% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $3.9 million in 2020, then surged by 385.42% to $18.7 million in 2021, then surged by 170.23% to $50.6 million in 2022, then declined by 5.01% to $48.0 million in 2023, then retreated by 13.31% to $41.6 million in 2024.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $41.6 million in Q3 2024, $38.6 million in Q2 2024, and $36.1 million in Q1 2024.